Medical therapy of endometrial cancer: Current status and promising novel treatments

Drugs

Volumn 72, Issue 5, 2012, Pages 705-713

  Hill, Emily K ^a   Dizon, Don S ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Angiogenesis inhibitors; Doxorubicin; Endometrial cancer; Epothilones; Paclitaxel

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERLOTINIB; ESTROGEN; EVEROLIMUS; GEFITINIB; IXABEPILONE; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROTEIN P16; PROTEIN P53; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ANEMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG ERUPTION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INTRAUTERINE CONTRACEPTIVE DEVICE; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MICROSATELLITE INSTABILITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NULLIPARA; OBESITY; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; PAIN; PNEUMONIA; PROTEINURIA; RECURRENT CANCER; REVIEW; THROMBOEMBOLISM; TUMOR DIFFERENTIATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL NEOPLASMS; EPOTHILONES; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES; TUBULIN MODULATORS;

MAMMALIA;

EID: 84858785303     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631840-000000000-00000     Document Type: Review

References (68)

1. Jemal A, Seigel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300
2. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335 (7630): 1134
3. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies. Lancet 2008; 371: 569-78 (Pubitemid 351232031)
4. Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011 Dec; 205 (6): 518-25
5. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101 (2): 322-6
6. McMeekin DS, Alektiar KM, Sabbatini PJ, et al. Corpus: epithelial tumors. In: Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. Philadelphia (PA): Lipponcott, 2009: 683-732
7. Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol 2011; 54 (2): 215-8
8. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008; 111: 436-47 (Pubitemid 351653438)
9. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005 Aug; 106 (2): 413-25
10. Sorbe B, Nordström B, Mäenpä ä J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19 (5): 873-8
11. NCCN clinical practice guidelines in Oncology (NCCN guidelines) uterine neoplasms. Version 1.2012. 2011 Aug 11 [online]. Available from URL: http://www.nccn.org/pro fessionals/physician-gls/pdf/uterine.pdf [Accessed 2012 Feb 20]
12. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-51 (Pubitemid 38251372)
13. Creutzberg CL, van Putten WLJ, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. Lancet 2000; 355: 1404-11 (Pubitemid 30215963)
14. Blake P, Swart Am, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373: 137-46
15. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-23
16. Sorbe B, Horvath G, AnderssonH, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective randomised study. Int J Radiat Oncol Biol Phys 2011; 82 (3): 1249-55
17. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004; 95: 133-8 (Pubitemid 39286288)
18. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-44 (Pubitemid 29269242)
19. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 364-7 (Pubitemid 32112847)
20. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 10-4 (Pubitemid 38147365)
21. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4-9 (Pubitemid 38147364)
22. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006; 24: 36-44 (Pubitemid 46630491)
23. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediateand high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-33 (Pubitemid 350299451)
24. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95: 266-71 (Pubitemid 44187586)
25. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 543-52
26. Hogberg T, Signorelli M, Freire de Oliveira C, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer: results from two randomized studies. Eur J Cancer 2010; 46: 2422-31
27. Gynecologic Oncology Group. Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer [ClinicalTrials.gov identifier NCT00807768]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Aug 7]
28. Gynecologic Oncology Group. Carboplatin and paclitaxel with or without cisplatin and radiation therapy in treating patients with stage III or stage IVa endometrial cancer [ClinicalTrials.gov identifier NCT00942357]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Aug 7]
29. Leiden University Medical Center. Chemotherapy and radiation therapy compared with radiation therapy alone in treating patients with high-risk stage I, stage II, or stage III endometrial cancer. [ClinicalTrials.gov identifier NCT00411138]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinical trials.gov [Accessed 2011 Sep 6]
30. Fleming GF. Systematic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25: 2983-90 (Pubitemid 47123163)
31. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278-81 (Pubitemid 26274811)
32. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 277-81 (Pubitemid 36335809)
33. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 3902-8 (Pubitemid 41079871)
34. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15: 1173-8 (Pubitemid 39199303)
35. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159-66 (Pubitemid 41095150)
36. Gerth K, Bedorf N, Hoe G, et al. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot 1996; 49: 560-3 (Pubitemid 26235665)
37. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008; 13: 1207-23
38. Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008; 63: 157-66
39. Lee F, Covello KL, Castaneda S, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008; 14 (24): 8123-31
40. Hussain M, Tangen CM, Lara Jr PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724-9 (Pubitemid 46211517)
41. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439-46
42. Vansteenkiste J, Lara Jr PN, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25: 3448-55 (Pubitemid 47310882)
43. Burtness BA, Manola J, Axelrod R, et al., Eastern Cooperative Oncology Group. A randomized phase II study of ixabepilone (BMS-247550) given daily · 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19: 977-83 (Pubitemid 351627317)
44. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407-14 (Pubitemid 47310876)
45. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399-406 (Pubitemid 47310875)
46. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415-20 (Pubitemid 47310877)
47. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol 2009; 27: 3104-8
48. Bristol-Myers Squibb. A study of ixabepilone as second line therapy for locally advanced, recurrent or metastatic endometrial cancer (IXAMPLE2) [ClinicalTrials.gov identifier NCT00883116]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Aug 8]
49. Gynecologic Oncology Group. Paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab in treating patients with stage III, stage IV, or recurrent endometrial cancer [ClinicalTrials.gov identifier NCT00977574]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Aug 15]
50. Hecht J, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24 (29): 4783-91 (Pubitemid 46630943)
51. Mutter GL. PTEN, a protean tumor suppressor. Am J Pathol 2001; 158 (6): 1895-8 (Pubitemid 32545170)
52. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16 (1): 8-13
53. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011 Aug 20; 29 (24): 3278-85
54. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [abstract no. 5516]. J Clin Oncol 2007; 25: 278
55. Slomovitz BM, Lu KH, Johnson T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010; 116 (23): 5415-9
56. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487-95
57. Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001; 80: 181-8 (Pubitemid 32158456)
58. Yokoyama Y, Sato S, Futagami M, et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000; 77: 413-8 (Pubitemid 30368560)
59. Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007; 27: 3525-8 (Pubitemid 47607497)
60. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial Cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2011; 29 (16): 2259-65
61. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008; 26: 4319-25
62. Leslie KK, SillMW, Darcy KM, et al. Efficacy and safety of gefitinib (Iressa, ZD1839) and potential prognostic value of soluble EGFR, EGFR mutations and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer [abstract no. e16542]. J Clin Oncol 2009; 27 Suppl.
63. Slomovitz B, Schmeler K, Miller D, et al. Phase II study of cetuximab (erbitux) in patients with progressive or recurrent endometrial cancer [abstract]. Gynecol Oncol 2010; 116: 13 Suppl. 1
64. Konecny GE, Venkatesan N, Yan G, et al. Activity of lapatanib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008; 98: 1076-84 (Pubitemid 351399811)
65. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116: 15-20
66. Nimeiri H, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117: 37-40
67. Welch S, Hirte H, Schilder RJ, et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial [abstract no. 5084]. J Clin Oncol 2006; 24
68. Fleming GF, Morgan R, Wang L, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH Phase II consortium [abstract no. 5576]. J Clin Oncol 2009; 27